Ciprofloxacin Resistance and Gonorrhea Incidence Rates in 17 Cities, United States, 1991–2006, H. W. Chesson et al.
Antimicrobial resistance can hinder gonorrhea prevention and control
efforts. In this study, CDC wanted to see if antimicrobial resistance could
increase the number of gonorrhea cases. CDC analyzed antimicrobial resistance
data from the Gonococcal Isolate Surveillance Project (GISP) and city-level
gonorrhea incidence rates from surveillance data for 17 cities from 1991 to
2006. CDC’s analysis found a strong, positive association between ciprofloxacin
resistance and increased gonorrhea cases at the city level. Due to widespread
drug resistance, CDC has not recommended ciprofloxacin (a type of fluoroquinolone)
be used to treat gonorrhea since 2007. While the number of gonorrhea cases has
decreased since the 1970s, the organism is now becoming resistant to
cephalosporins, the foundation of the last available treatment option. Emerging
cephalosporin resistance could have substantial health and economic
consequences in the future. Efforts to control the spread of resistant strains
might reduce this potential burden.
0 comments :
Post a Comment